Current Urology Reports

, Volume 5, Issue 4, pp 274–279

The role of 5-α-reductase inhibition as monotherapy in view of the MTOPS data

  • Jaspreet S. Sandhu
  • Alexis E. Te
Article

Abstract

Medical treatment for the symptoms of benign prostatic hyperplasia (BPH) consists of α blockers and 5-α-reductase inhibitors. Data suggest that 5-α-reductase inhibitors can prevent progression of BPH and reduce the risk of BPH-related surgery, especially in men with large-volume prostates. Results from the largest randomized, prospective, placebo-controlled trial, the Medical Therapy of Prostatic Symptoms trial, have been presented. These results support the notion of using 5-α-reductase inhibitors for the prevention of BPH progression and BPH-related surgery. Furthermore, long-term 5-α-reductase inhibitor monotherapy, although slow in onset, is a viable therapy for symptom relief in men with mild to moderate symptoms.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Berry SJ, Coffey DS, Walsh PC, Ewing LL: The development of human benign prostatic hyperplasia with age. J Urol 1984, 132:474–479.PubMedGoogle Scholar
  2. 2.
    McConnell JD: Prostatic growth: new insights into hormonal regulation. Br J Urol 1995, 76(suppl 1):5–10.PubMedGoogle Scholar
  3. 3.
    Imperato-McGinley J, Guerrero L, Gautieer T, Peterson RE: Steroid 5-alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 1974, 186:1213–1215.PubMedCrossRefGoogle Scholar
  4. 4.
    McConnell JD, Barry MJ, Bruskewitz RC, et al.: Benign Prostatic Hyperplasia: Diagnosis and Treatment. Clinical Practice Guidelines. No. 8., AHCPR Publication No 94-0582. Rockville, MD: Agency for Health Care Policy and Research. Public Health Service, US Department of Health and Human Services, 1994.Google Scholar
  5. 5.
    Rhodes T, Girman CJ, Jacobsen SJ, et al.: Longitudinal prostate growth rates during 5 years in randomly selected men 40–79 years old. J Urol 1999, 161:1174–1179.PubMedCrossRefGoogle Scholar
  6. 6.
    Girman CJ, Jacobsen SJ, Guess HA, et al.: Natural history of prostatism: relationship among symptoms, prostate volume, and peak urinary flow rate. J Urol 1995, 153:1510–1515.PubMedCrossRefGoogle Scholar
  7. 7.
    Roehrborn CG, Boyle P, Bergner D, et al.: Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a 4-year, randomized trial comparing finasteride versus placebo. Urology 1999, 54:662–669. The first long-term study of 5-á-reductase, finasteride, in the treatment of BPH documenting safety and efficacy in a multicenter, randomized, placebo-controlled trial.PubMedCrossRefGoogle Scholar
  8. 8.
    Hoffman RM, MacDonald R, Slaton JW, Wilt TJ: Laser prostatectomy versus transurethral resection for treating benign prostatic obstruction: a systematic review. J Urol 2003, 169:210–215.PubMedCrossRefGoogle Scholar
  9. 9.
    Tunuguntla HS, Evans CP: Minimally invasive therapies for benign prostatic hyperplasia. World J Urol 2002, 20:197–206.PubMedGoogle Scholar
  10. 10.
    Gup DI, Shapiro E, Bauman M, Lepor H: Contractile properties of human prostate adenomas ant the development of infravesical obstruction. Prostate 1989, 15:105–114.PubMedCrossRefGoogle Scholar
  11. 11.
    Lepor H, Auerbach S, Puras-Baez A, et al.: A randomized, placebo-controlled, multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 1992, 148:1467–1474.PubMedGoogle Scholar
  12. 12.
    Fawzy A, Braun K, Lewis GP, et al.: Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J Urol 1995, 154:105–109.PubMedCrossRefGoogle Scholar
  13. 13.
    Gillenwater JY, Conn RL, Chrysant SG, et al.: Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild-to-moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study. J Urol 1995, 154:110–115.PubMedCrossRefGoogle Scholar
  14. 14.
    Lepor H: Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology 1998, 51:892–900.PubMedCrossRefGoogle Scholar
  15. 15.
    AUA Practice Guideline Committee: AUA Guidelines on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol 2003, 170:530–547. The recent publication of practice guidelines on the management of BPH by an AUA guideline committee. This publication is an update of the AHCPR guideline published in 1994.CrossRefGoogle Scholar
  16. 16.
    Gromley GJ, Stoner E, Bruskewitz RC, et al.: The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 1992, 327:1185–1191.CrossRefGoogle Scholar
  17. 17.
    Beisland HO, Binkowitz B, Brekkan E, et al.: Scandinavian clinical study of finasteride in the treatment of benign prostatic hyperplasia. Eur Urol 1992, 22:271–277.PubMedGoogle Scholar
  18. 18.
    Lepor H, Williford WO, Barry MJ, et al.: The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 1996, 335:533–539.PubMedCrossRefGoogle Scholar
  19. 19.
    McConnell JD, Bruskewitz R, Walsh P, et al.: The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998, 338:557–563.PubMedCrossRefGoogle Scholar
  20. 20.
    Bruskewitz R, Girman CJ, Fowler J, et al.: Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. Urology 1999, 54:670–678.PubMedCrossRefGoogle Scholar
  21. 21.
    Kaplan SA, Holtgrewe HL, Bruskewitz R, et al.: Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia. Urology 2001, 57:1073–1077.PubMedCrossRefGoogle Scholar
  22. 22.
    Matsumoto AM, Tenover L, McClung M, et al.: The long-term effect of specific type II 5-alpha-reductase inhibition with finasteride on bone mineral density in men: results of a 4-year placebo controlled trial. J Urol 2002, 167:2105–2108.PubMedCrossRefGoogle Scholar
  23. 23.
    Schafer W, Tammela TL, Barrett DM, et al.: Continued improvement in pressure-flow parameters in men receiving finasteride for 2 years. Urology 1999, 54:278–283.PubMedCrossRefGoogle Scholar
  24. 24.
    Bautista OM, Kusek JW, Nyberg LM, et al.: Study design of the Medical Therapy of Prostate Symptoms (MTOPS) trial. Control Clin Trials 2003, 24:224–243.PubMedCrossRefGoogle Scholar
  25. 25.
    McConnell J: The impact of medical therapy on clinical progression of BPH: results of MTOPS trial [Abstract]. J Urol 2002, 1042:265. The first public presentation of the MTOPS data at the national AUA meeting.Google Scholar
  26. 26.
    Roehrborn CG, Boyle P, Nickel JC, et al.: Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002, 60:434–441. This study confirmed the safety and efficacy of 5-á-reductase therapy with a dual type-1 and type-2 5-á-reductase inhibitor therapy.PubMedCrossRefGoogle Scholar
  27. 27.
    Lowe FC, McConnell JD, Hudson PB, et al.: Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia. Urology 2003, 61:791–796.PubMedCrossRefGoogle Scholar
  28. 28.
    Lam JS, Romas NA, Lowe FC: Long-term treatment with finasteride in men with symptomatic benign prostatic hyperplasia: 10-year follow-up. Urology 2003, 61:354–358.PubMedCrossRefGoogle Scholar
  29. 29.
    Baldwin KC, Ginsberg PC, Roehrborn CG, Harkaway RC: Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia. Urology 2001, 58:203–208.PubMedCrossRefGoogle Scholar
  30. 30.
    Barkin J, Guimaraes M, Jacobi G, et al.: Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5-alpha-reductase inhibitor dutasteride. Eur Urol 2003, 44:461–466.PubMedCrossRefGoogle Scholar
  31. 31.
    Thompson IM, Goodman PJ, Tangen CM, et al.: The influence of finasteride on the development of prostate cancer. N Engl J Med 2003, 349:215–224.PubMedCrossRefGoogle Scholar
  32. 32.
    Scardino PT: The prevention of prostate cancer: the dilemma continues. N Engl J Med 2003, 349:297–299.PubMedCrossRefGoogle Scholar
  33. 33.
    Kearney MC, Bingham JB, Bergland R, et al.: Clinical predictors in the use of finasteride for control of gross hematuria due to benign prostatic hyperplasia. J Urol 2002, 167:2489–2491.PubMedCrossRefGoogle Scholar
  34. 34.
    Pareek G, Shevchuk M, Armenakas NA, et al.: The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: a possible mechanism for decreased prostatic bleeding in treated patients. J Urol 2003, 169:20–23.PubMedCrossRefGoogle Scholar
  35. 35.
    Hagerty JA, Ginsberg PC, Harmon JD, Harkaway RC: Pretreatment with finasteride decreases perioperative bleeding associated with transurethral resection of the prostate. Urology 2000, 55:684–689.PubMedCrossRefGoogle Scholar
  36. 36.
    Donahue JF, Sharma H, Abraham R: Transurethral prostate resection and bleeding: a randomized, placebo-controlled trial of the role of finasteride for decreasing operative blood loss. J Urol 2002, 168:2024–2026.CrossRefGoogle Scholar

Copyright information

© Current Science Inc 2004

Authors and Affiliations

  • Jaspreet S. Sandhu
    • 1
  • Alexis E. Te
    • 1
  1. 1.Brady Prostate Center, Department of UrologyNew York Presbyterian HospitalNew YorkUSA

Personalised recommendations